Q10214: S. H. Kizilbash, et al. In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models
May Be Limited by Tissue Binding and Compensatory Signaling. Molecule Cancer Therapeutics 2021;20(6):1009-1018
Agents: Tesevatinib Vehicle: DMSO; Route: IP; Species: Mice; Pump: 1003D; Duration: 48 hours;
ALZET Comments: "Dose: (1 uL/h); Controls received mp w/ vehicle; animal info: FVB wild-type (WT) mice and (TKO)
8 to 14 weeks; half-life (p.3); Tesevatinib is a potent oral brain penetrant EGFR inhibitorcancer (Glioblastoma )"
Q10318: H. S. Huang, et al. Insuline-Like Growth Factor-2 (IGF2) and Hepatocyte Growth Factor (HGF) Promote
Lymphomagenesis in p53-null Mice in Tissue-specific and Estrogen-signaling Dependent Manners. Journal of Cancer Research
and Clinical Oncology 2021;12(20):6021-6030
Agents: Estrogen Vehicle: PBS; Route: SC; Species: Mice; Pump: 1004; Duration: 28 days;
ALZET Comments: Dose: (80 nM); Controls received mp w/ vehicle; animal info: male Trp53-/- mice, wild type strain
C57BL6/Jcancer (Lymphoma); dependence;